Immunomodulation and Immunotherapy for Patients with Prostate Cancer: An Up-to-Date Review
Open Access
- 12 May 2025
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 13 (5) , 1179
Abstract
Immunotherapy alone or in combination with chemotherapy or radiotherapy is the frontline treatment for melanoma and lung cancer. However, its role in prostate cancer is usually as a fourth-line treatment. It is usually employed in patients with metastasis, after androgen blockade and chemotherapy. This article reviews the immunosuppressive effects of prostate cancer and possible uses of various types of immunotherapies. It also considers when would be the optimal time to employ this type of therapy.Keywords
All Related Versions
This publication has 174 references indexed in Scilit:
- Single‐cell analysis of localized prostate cancer patients links high Gleason score with an immunosuppressive profileThe Prostate, 2023
- The theory of tumor ecosystemCancer Communications, 2022
- Ductal and acinar components of mixed prostatic adenocarcinoma frequently have a common clonal originThe Prostate, 2022
- Long‐term first‐in‐man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high‐risk prostate cancer after radical prostatectomyThe Prostate, 2021
- The 27th Annual Prostate Cancer Foundation Scientific Retreat ReportThe Prostate, 2021
- Imaging expression of prostate‐specific membrane antigen and response to PSMA‐targeted β‐emitting radionuclide therapies in metastatic castration‐resistant prostate cancerThe Prostate, 2021
- Ductal adenocarcinoma of the prostate: A systematic review and meta‐analysis of incidence, presentation, prognosis, and managementBJUI Compass, 2021
- PTEN‐deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cellsThe Prostate, 2019
- PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapyJournal of Cellular Physiology, 2019
- Induction of myeloid‐derived suppressor cells by tumor exosomesInternational Journal of Cancer, 2009